This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
At MY SALON Suite Oakland , California, Vee Vargas is not only creating stunning hair but also inspiring an entire industry with her visionary work. As the owner of Be Here Salon at MY SALON Suite , she is at the forefront of innovation and empowerment, shaping a future where beauty spaces are inclusive and nurturing for all. A Visionary Recognized Vee Vargas’s innovative approach and dedication have earned her a finalist spot for the prestigious NAHA Award for Inspiring Salon of the Year
Welcome back to The Beauty Biz Show! In this episode, double board-certified dermatologist and experienced inventor Dr. Steven Hacker joins Lori to discuss his entrepreneurial journey, the role of estheticians in dermatology, and all things dermaplaning. Tune in to learn more about Dr. Hacker’s latest invention, the Lumohs Dermaplane, and how it can transform your esthetics practice.
In Day 10 of revealing our 2025 SALON TODAY 200, we visit the second half of the Growth honorees, including the team from Studio Wish in Twinsburg, Ohio.
Mohs surgery is a specialized, highly effective technique for the removal of skin cancer. Among treatment options, Mohs surgery uniformly produces the highest success rate and has the lower risk of tumor recurrence. However, for many prospective patients the idea of undergoing Mohs surgery can feel intimidating. It is natural to have concerns about what the procedure entails and how the day will unfold.
Tildrakizumab-asmn (Ilumya, Sun Pharmaceutical Industries, Inc.) improves moderate-to-severe nail psoriasis, according to new research presented at the 2025American Academy of Dermatology(AAD) Annual Meeting in Orlando, FL. Th e Phase 3b, randomized, double-blind, placebo-controlled clinical trial included 99 patients with moderate-to-severe plaque psoriasis.
Heart disease remains a leading cause of death worldwide, and early detection is key to improving outcomes. According to Dr. Aubrey Chad Hartmann of U.S. Dermatology Partners Cedar Park , While many people associate cardiovascular disease with symptoms like chest pain or shortness of breath, your skin also serves as an early warning system for underlying heart problems.
Heart disease remains a leading cause of death worldwide, and early detection is key to improving outcomes. According to Dr. Aubrey Chad Hartmann of U.S. Dermatology Partners Cedar Park , While many people associate cardiovascular disease with symptoms like chest pain or shortness of breath, your skin also serves as an early warning system for underlying heart problems.
At AAD 2025, Karan Lal, DO, MS, FAAD, presented clinical insights on insulated microneedling tips, grounding pad issues in monopolar radiofrequency, and more.
Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. The IGNITE study was a 24-week, randomized, placebo-controlled, double-blind study to assess the efficacy, safety and tolerability of rocatinlimab monotherapy every four weeks in 769 adults with moderate to severe AD, including patients previously treat
More than 63% of hidradenitis suppurativa (HS) patients who took bimekizumab (Bimzelx, UCB) for two years had no or mild skin pain, a substantial improvement from 10% at baseline. Of 425 HS patients with one or more draining tunnel (DT) at baseline, 55.7% had no DTs at two years of treatment. Christopher Sayed, MD, a Dermatologist at the University of North Carolina Chapel Hills HS Clinic in Durham, NC, discusses the results of the study, which were presented at the American Academy of Dermatolo
Stark highlighted Bimzelxs role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.
Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.
According to a poster from AAD, the National Psoriasis Foundations treatment goals were used as a benchmark to determine the risk of developing psoriatic arthritis after initiating biologics.
Panelists discuss the areas of research that need more attention in pediatric atopic dermatitis (AD) management, highlighting gaps in understanding the long-term effects of treatments, the genetic underpinnings of the disease, and strategies for improving early diagnosis and personalized care.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
76 
Let's personalize your content